← Leaderboards
Charles D Smith
Apogee Biotechnology Corporation
$4,163,780
Attributed
$4,163,780
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $882.7K · FY2014–24$1M$750K$500K$250K$0
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$4,163,780 · 4
By mechanism
R44$3,714,664 · 2
R43$449,116 · 2
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Sphingosine Kinase”
- Sarah Spiegel · Virginia Commonwealth University$17,020,055
- Viswanathan Natarajan · Johns Hopkins University$12,561,108
- Timothy Tun Hla · Boston Children'S Hospital$9,916,917
- Kevin R Lynch · University Of Virginia$7,626,626
- Julie D Saba · University Of California, San Francisco$7,382,760
- Thomas Michel · Brigham And Women'S Hospital$6,662,335
Research focus
Sphingosine KinaseSolid NeoplasmSphingolipidsDoseRadiationSphingosine 1-PhosphatePharmaceutical PreparationsSmall Business Innovation Research GrantClinical TrialsNovel TherapeuticsC-Myc GenesSafetyIn VivoCeramidesApoptosisDrug KineticsResearch Clinical TestingMultiple MyelomaPharmacodynamic BiomarkerNeoplastic CellPhase Ii Clinical TrialsInhibitor/AntagonistPlasmaTumor
Grant awards (7)
Opaganib as a Medical Countermeasure for Gastrointestinal Acute Radiation Syndrome$882,744
R44 · FY2024 · AI · contact PI
Opaganib as a Medical Countermeasure for Gastrointestinal Acute Radiation Syndrome$852,174
R44 · FY2023 · AI · contact PI
Treatment of Neuroblastoma by Inhibition of Sphingosine Kinase$225,000
R43 · FY2019 · CA · contact PI
Clinical Trial of ABC294640 in Patients with Refractory Multiple Myeloma$653,219
R44 · FY2017 · CA · contact PI
Clinical Trial of ABC294640 in Patients with Refractory Multiple Myeloma$659,861
R44 · FY2016 · CA · contact PI
Clinical Trial of ABC294640 in Patients with Refractory Multiple Myeloma$666,666
R44 · FY2015 · CA · contact PI
Protection Against Chemotherapy-Induced Gastrointestinal Mucositis by a Sphingosi$224,116
R43 · FY2014 · DK · contact PI